EU drugs regulator endorses changes to remdesivir marketing for COVID-19 use


  • World
  • Friday, 11 Dec 2020

FILE PHOTO: An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/File Photo

(Reuters) - Europe's drugs regulator on Friday recommended changing some terms of the conditional approval given to antiviral drug remdesivir as a COVID-19 treatment, to make clear the conditions under which it can be used.

Doubts over remdesivir's effectiveness were raised after the World Health Organization (WHO) last month said the drug should not be used for COVID-19 patients, regardless of how ill they are, just months after Europe and the United States approved the treatment.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

Feature: Chinese firms eager to showcase new products at Spain seafood fair
Slovenia's jobless rate falls to historic low
Crude futures settle higher
U.S. dollar ticks up
Turkish court sentences Syrian woman to life in prison over Istanbul bombing
Students at Stanford University hold pro-Palestine demonstration
At least 10 killed in hotel fire in southern Brazil
Interview: Hopes of rate cuts driving FTSE 100 rally, says LSE expert
Israeli shekel falls to over 5-month low against USD
UM Consumer Sentiment Index falls in April

Others Also Read